Rare disease medicines for the United States
The generic promise, kept.
When a rare disease medicine loses exclusivity, patients are supposed to get a lower price without giving anything up. Too often nobody shows up. We do: high quality medicines, priced below the brand, with the supply and support these families depend on left intact.
Who we are
One standard runs through everything we build: a patient should be able to get their medicine, afford it, and keep it.
Covara develops and commercializes high quality alternatives to rare disease brands whose protection has ended. We manufacture to United States standards, build redundancy into supply before launch rather than after a shortage, and carry the full patient support these communities depend on.
We are a development stage company. Today that means selection, development, and building the quality and commercial systems these products will launch onto.
Supply you can count on
These patients have no second option. Redundant manufacturing and a qualified second source of active ingredient are conditions of taking a program forward, and we hold a published stock floor rather than running lean.
A real price difference
We enter below the brand we compete with, every time, and publish the rules we hold ourselves to. Where we are the only supplier keeping a product available, we price on cost, not leverage.
Support that does not disappear
Benefits navigation, prior authorization help, financial assistance, and nurse support are part of the therapy, not a marketing line. We build them for the patients standard programs leave out.
Why we exist
Losing exclusivity does not automatically mean patients get a better deal.
In large markets, competition arrives on its own. In rare disease it often does not, because entering costs the same whether a medicine serves a few hundred patients or a few million. Three things happen instead.
Nobody enters at all
The brand price simply persists. Nothing forces it down, and patients never see the benefit that the end of exclusivity was supposed to deliver.
The support leaves with the brand
A low cost version arrives, but the hub, the nurse line, and the copay assistance leave with the brand. Patients start later, and some stop entirely.
Supply becomes fragile
One supplier with one source of active ingredient serves a market too small to attract a second. Any interruption becomes a shortage for people with no alternative.
How we work
Most of the value is created before development begins.
We say no to far more programs than we take forward, because no commercial plan rescues the wrong medicine.
Select
Every candidate meets the same criteria: a clean regulatory path, a concentrated specialist prescriber base, a real barrier beyond the molecule, and a second source of active ingredient we can qualify. Fail one and the program stops.
Develop and manufacture
Formulation, analytical development, bioequivalence, and filing, run with partners chosen on inspection history rather than price. Quality and pharmacovigilance systems are built to carry a portfolio, not one product.
Launch and support
Controlled specialty distribution, a patient support hub, and clinical help for the parts of therapy where real world use breaks down. All of it live on day one.
Improve
Where a different formulation, route, or strength would meaningfully help patients, we develop it and seek approval on its own merits. The improvement has to be real, judged by the regulator.
Pipeline
A portfolio built one qualified program at a time.
Our programs address rare conditions where options are limited, prescribing is concentrated among specialists, and supply reliability matters as much as price.
| Program | Approach | Stage |
|---|---|---|
| Lead program | Abbreviated pathway | Development |
| Second program | Abbreviated pathway | Selected |
| Reformulation program | Improved formulation | Feasibility |
Stages are Selected, Development, Filed, Under review, and Available. Program details, including therapeutic area, are disclosed under confidentiality. Additional candidates are under evaluation. No Covara product is approved or available for prescription.
Our commitments
Trust in this category is earned with commitments, not intentions.
This corner of the industry was damaged by companies that acquired a medicine nobody else supplied and then priced it accordingly. We are building the opposite, and making these commitments before the first product, not after.
Published pricing rules
We enter below the brand we compete with, price on cost wherever we are the sole supplier, and cap our own annual increases. The framework is published, and we report against it.
Supply reliability
Redundant manufacturing, a qualified second source of active ingredient, and a published minimum stock floor. Reliability is a design requirement, not a response to a shortage.
Support built for who is actually there
Rare disease populations are heavily represented in government insurance, where standard assistance programs do not reach. Ours is designed and staffed for those patients, within the rules that govern it.
Bringing back what was abandoned
A fixed share of revenue is reserved to return discontinued rare disease products to market, selected against published criteria. A standing capital commitment, not a grant program.
Leadership
The team has done this before.
Covara is led by operators with direct experience in rare disease commercialization, manufacturing and quality, and specialty distribution.
Name
Chief Executive Officer
Two sentences: prior companies, the launches or approvals they carried, what they own here.
Name
Chief Business Officer
Two sentences: prior companies, the launches or approvals they carried, what they own here.
Name
Head of Technical Operations
Two sentences: prior companies, the launches or approvals they carried, what they own here.
Work with us
Who we would like to hear from.
Investors
Investors who understand specialty pharmaceutical portfolios and want returns that do not depend on a clinical readout.
Manufacturing and API partners
Finished dose manufacturers and active ingredient suppliers with strong inspection histories, able to serve low volume, high reliability programs.
Specialty pharmacy and distribution
Partners who can give treatment centers a real choice and patients a fast, predictable path to first fill.
Companies with a product they can no longer support
If you hold a rare disease product that no longer fits your portfolio, we will keep supplying the patients on it.
Contact
Start a conversation.
We respond to every serious inquiry. For investor materials, include your firm and focus area.
- Investor inquiries investors@covaratx.com
- Partnering and business development partnering@covaratx.com
- General info@covaratx.com